Marta Woszynska
speaker
23 appearances
1 recordings
1 series
first heard Feb 2026
last heard 26 Feb
Marta Woszynska’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.
Appearances
Compounding laws...
have a lot of loopholes.
So if pharmacies were to customize the product, which is really how compounding is supposed to be done, they can continue compounding even though the drug is not in shortage.
The issue is, is that the law doesn't sort of draw a line between the scale for compounding versus when it becomes commercial manufacturing.
They have incredible power of what products they allow through the border.
They don't have to see that there is an actual problem with the product.
They just need to suspect that there is a problem with the product.
My take on this is that the landscape dramatically changed.
You now have Novo and Eli Lilly participating with the Trump administration in these most favorite nation agreements.
They are on Trump RX.
They have now really leaned in, dropped their prices quite a bit.
Now FGA has a lot more of an ability to now use those tools and protect those deals that they have basically made with these two manufacturers.
The fact that they're now shifting towards selling pills really makes a difference in terms of the ability to produce a lot of product quickly.
Injectable products really have major bottlenecks in production.
My concern was that the compounding pharmacies have been importing
product that's basically where the company sets their own standards.
They can decide what kinds of impurities they're going to test.
They decide what is an appropriate level of impurities.
They decide what is considered a pure product.
That makes me very nervous that we don't have a set standard for these products, and it's being used by millions of patients.
Showing 1–20 of 23 · page 1 of 2
Next →